Abstract
Human epidermal growth factor receptor 2 (HER2) is over-expressed in 15% – 30% of breast cancers. Women with HER2-positive breast cancer tend to have more aggressive cancer, increased risk of recurrence, and less favorable survival outcomes than women with HER2-negative breast cancer. This review focuses on HER2 and its role in breast cancer pathogenesis. We begin by providing background information on the biological function of HER2 and how this gene contributes to breast cancer development and progression. Next, we review the ongoing debate surrounding the accuracy of available modalities for detecting HER2, namely fluorescence in-situ hybridization (FISH) versus immunohistochemistry (IHC). We include current data examining the relationship between HER2 and possible genetic modifiers, such as topoisomerase IIα, BRCA1, and genomic instability in breast cancer subjects, and how these relationships may influence response to current therapies directed against HER2. We then discuss trastuzumab, a monoclonal antibody used to treat HER2+ breast cancers, and, after providing an overview of the molecular processes involved in targeted therapy, we summarize the current literature regarding outcomes, as well as the potential impact on the overall health of patients, with special attention to cardiac risk involved with such therapy. Finally, we touch on future directions in this field, including newer targeted therapies in development.
Keywords: HER2, breast cancer, human epidermal growth factor receptor
Current Cancer Therapy Reviews
Title: HER2 in the Era of Molecular Medicine: A Review
Volume: 4 Issue: 1
Author(s): Karen A. Callaghan, Rachel E. Ellsworth, Darrell L. Ellsworth and Craig D. Shriver
Affiliation:
Keywords: HER2, breast cancer, human epidermal growth factor receptor
Abstract: Human epidermal growth factor receptor 2 (HER2) is over-expressed in 15% – 30% of breast cancers. Women with HER2-positive breast cancer tend to have more aggressive cancer, increased risk of recurrence, and less favorable survival outcomes than women with HER2-negative breast cancer. This review focuses on HER2 and its role in breast cancer pathogenesis. We begin by providing background information on the biological function of HER2 and how this gene contributes to breast cancer development and progression. Next, we review the ongoing debate surrounding the accuracy of available modalities for detecting HER2, namely fluorescence in-situ hybridization (FISH) versus immunohistochemistry (IHC). We include current data examining the relationship between HER2 and possible genetic modifiers, such as topoisomerase IIα, BRCA1, and genomic instability in breast cancer subjects, and how these relationships may influence response to current therapies directed against HER2. We then discuss trastuzumab, a monoclonal antibody used to treat HER2+ breast cancers, and, after providing an overview of the molecular processes involved in targeted therapy, we summarize the current literature regarding outcomes, as well as the potential impact on the overall health of patients, with special attention to cardiac risk involved with such therapy. Finally, we touch on future directions in this field, including newer targeted therapies in development.
Export Options
About this article
Cite this article as:
Callaghan A. Karen, Ellsworth E. Rachel, Ellsworth L. Darrell and Shriver D. Craig, HER2 in the Era of Molecular Medicine: A Review, Current Cancer Therapy Reviews 2008; 4 (1) . https://dx.doi.org/10.2174/157339408783565529
DOI https://dx.doi.org/10.2174/157339408783565529 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Chronic Eosinophilic Leukemia, Not Otherwise Specified (CEL, NOS)
Current Cancer Therapy Reviews Phosphorylated and O-GlcNAc Modified IRS-1 (Ser1101) and -2 (Ser1149) Contribute to Human Diabetes Type II
Protein & Peptide Letters Re-Wiring the Circuit: Mitochondria as a Pharmacological Target in Liver Disease
Current Medicinal Chemistry Gemcitabine-Related Atrial Fibrillation: A Case Report and Review of the Literature
Current Drug Safety Polyamines and Related Nitrogen Compounds in the Chemotherapy of Neglected Diseases Caused by Kinetoplastids
Current Topics in Medicinal Chemistry Immunoglobulin Therapy, Myocardial Diseases and Atherosclerosis:Recent Experimental and Clinical Studies
Current Cardiology Reviews The ABCA2 Transporter: Intracellular Roles in Trafficking and Metabolism of LDL-Derived Cholesterol and Sterol-Related Compounds
Current Drug Metabolism Cardiovascular Magnetic Resonance for Evaluation of Heart Involvement in ANCA-Associated Vasculitis. A Luxury or a Valuable Diagnostic Tool?
Inflammation & Allergy - Drug Targets (Discontinued) Diabetes, the Renin-Angiotensin System and Heart Disease
Current Vascular Pharmacology Dietary Prevention of Coronary Heart Disease
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Glucocorticoids and the Cardiovascular System: State of the Art
Current Pharmaceutical Design Tracking the Mesenchymal Stem Cell Fate After Transplantation Into the Infarcted Myocardium
Current Stem Cell Research & Therapy Neuroimmune Activation in Chronic Heart Failure
Endocrine, Metabolic & Immune Disorders - Drug Targets The GH/IGF-1 Axis and Heart Failure
Current Cardiology Reviews Functions of Fukutin, a Gene Responsible for Fukuyama Type Congenital Muscular Dystrophy, in Neuromuscular System and Other Somatic Organs
Central Nervous System Agents in Medicinal Chemistry Myocardial Structure and Matrix Metalloproteinases
Current Topics in Medicinal Chemistry Gender Differences in the Effects of Angiotensin Receptor Blockers on Cardiovascular Disease
Current Pharmaceutical Design Cardiovascular Diseases in Pregnancy - A Brief Overview
Current Cardiology Reviews Myocardial Quantitative Analysis in Physiological and Pathological Ventricular Hypertrophy: The Increasing Role of Doppler Myocardial Imaging
Current Cardiology Reviews Targeting Generation of Antibodies Specific to Conformational Epitopes of Amyloid β-Derived Neurotoxins
CNS & Neurological Disorders - Drug Targets